Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 4, 2008, Pages 884-891

  Lucchi, M ^a   Damle, B ^b   Fang, A ^b   de Caprariis, P J ^b   Mussi, A ^a   Sanchez, S P ^b   Pasqualetti, G ^a   Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b PFIZER INC   (United States)

Author keywords

Antibiotic accumulation; Azalides; Macrolides; Respiratory tract

Indexed keywords

AZITHROMYCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG INFECTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; THORAX SURGERY; TRACHEOBRONCHIAL TOILET;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LUNG; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; SERUM; TISSUE DISTRIBUTION;

EID: 41149168759     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn032     Document Type: Article

References (23)

1. Azithromycin. Package insert. New York, NY, Pfizer Inc., 2006.
2. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 (Suppl. 3): 233-7.
3. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2001; 14: 165-72.
4. Girard D, Finegan SM, Dunne MW et al. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 2005; 56: 365-71.
5. Di Paolo A, Barbara C, Chella A et al. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res 2002; 46: 545-50.
6. Danesi R, Lupetti A, Barbara C et al. Comparative distributon of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 2003; 51: 939-45.
7. Conte JE, Golden J, Duncan S et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996; 40: 1617-22.
8. Rennard SI, Basset G, Lecossier D et al. Estirration of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532-8.
9. Baldwin DR, Wise R, Andrews JM et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3: 886-90.
10. Liu P, Allaudeen H, Chandra R et al. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate- release regimen. Antimicrob Agents Chemother 2007; 51: 103-9.
11. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886-99.
12. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001; 18: 71 -6.
13. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998; 32: 785-93.
14. A0661124 Final Clinical Study Report. An open-label, randomized, 2-way crossover study to evaluate the bioequivalence of a single 2-gram dose of azithromycin sustained release oral powder for suspension between the ICH drug supplies and the Phase 3 study drug supplies in healthy adult subjects. New York, NY: Pfizer Inc., 2004.
15. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: Link between quality of care and resource utilization. Arch Intern Med 2002; 162: 682-8.
16. Houck PM, Bratzler DW, Nsa W et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-Acquired pneumonia. Arch Intern Med 2004; 164: 637-44.
17. Rodvold KA, Goffried MH, Danziger LH et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997; 41 1399-402.
18. Firsov AA, Zinner SH, Vostrov SN et al. Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. J Antimicrob Chemother 2002; 49: 113-9.
19. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifloxacin, levoffoxacin, and azithromycin in older adults. Chest 2004; 125: 965-73.
20. Craig WA, Kiem S, Andes DR. Free drug 24-h AUC/MIC is the PKIPD target that correlates with in vivo efficacy of macrolides, azalides, ketolides, and clindamycin. In: Abstracts of the Forty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 2002. Abstract A-1264. American Society for Microbiology, Washington, DC, USA.
21. Drehobl MA, De Salvo MC, Lewis DE et al. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128: 2230-7.
22. D'Ignazio J, Camere MA, Lewis DE et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035-41.
23. Murray JJ, Emparanza P, Lesinskas E et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005; 133: 194-200.